{"schema_version":"secwatch.filing_event.v1","accession":"0001472375-23-000134","form_type":"8-K","ticker":"RGPX","cik":"0001357878","company_name":"REGENEREX PHARMA, INC.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.695509+00:00","generated_at":"2026-06-10T07:31:23.644571+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Regenerex Pharma announces 95% wound closure rate and Q4 2023 manufacturing plans","bullets":["Products Xcellderma and Accelerex target chronic wounds via proprietary QBx ingredient.","Claims 95% of chronic wounds show 100% closure within 90 days in clinical evaluations.","Manufacturing to begin in Q4 2023 at facility in Memphis, TN.","No specific management officer or director names were provided in the update.","Products are FDA-cleared or OTC; Accelerex is a prescription-only combination device."],"urls":{"canonical":"https://secwatch.observer/filing/0001472375-23-000134","json":"https://secwatch.observer/filing/0001472375-23-000134.json","markdown":"https://secwatch.observer/filing/0001472375-23-000134.md","text":"https://secwatch.observer/filing/0001472375-23-000134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357878/000147237523000134/0001472375-23-000134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357878/000147237523000134/ixform8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:31:23.644571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}